338 related articles for article (PubMed ID: 25645567)
1. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
Blonde L; Pencek R; MacConell L
Cardiovasc Diabetol; 2015 Feb; 14():12. PubMed ID: 25645567
[TBL] [Abstract][Full Text] [Related]
2. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
Bergenstal RM; Li Y; Porter TK; Weaver C; Han J
Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
[TBL] [Abstract][Full Text] [Related]
3. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
Simó R; Guerci B; Schernthaner G; Gallwitz B; Rosas-Guzmàn J; Dotta F; Festa A; Zhou M; Kiljański J
Cardiovasc Diabetol; 2015 Sep; 14():116. PubMed ID: 26338040
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
[TBL] [Abstract][Full Text] [Related]
6. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
Buse JB; Drucker DJ; Taylor KL; Kim T; Walsh B; Hu H; Wilhelm K; Trautmann M; Shen LZ; Porter LE;
Diabetes Care; 2010 Jun; 33(6):1255-61. PubMed ID: 20215461
[TBL] [Abstract][Full Text] [Related]
7. Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
Trautmann ME; Han J; Ruggles J
Clin Ther; 2016 Jun; 38(6):1464-1473. PubMed ID: 27126504
[TBL] [Abstract][Full Text] [Related]
8. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.
Chiquette E; Toth PP; Ramirez G; Cobble M; Chilton R
Vasc Health Risk Manag; 2012; 8():621-9. PubMed ID: 23166441
[TBL] [Abstract][Full Text] [Related]
9. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
[TBL] [Abstract][Full Text] [Related]
10. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
[TBL] [Abstract][Full Text] [Related]
11. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
[TBL] [Abstract][Full Text] [Related]
12. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
Wysham CH; MacConell LA; Maggs DG; Zhou M; Griffin PS; Trautmann ME
Mayo Clin Proc; 2015 Mar; 90(3):356-65. PubMed ID: 25744115
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Aroda VR; DeYoung MB
Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
Holman RR; Bethel MA; George J; Sourij H; Doran Z; Keenan J; Khurmi NS; Mentz RJ; Oulhaj A; Buse JB; Chan JC; Iqbal N; Kundu S; Maggioni AP; Marso SP; Öhman P; Pencina MJ; Poulter N; Porter LE; Ramachandran A; Zinman B; Hernandez AF
Am Heart J; 2016 Apr; 174():103-10. PubMed ID: 26995376
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
Molina Vega M; Muñoz-Garach A; Tinahones FJ
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
[TBL] [Abstract][Full Text] [Related]
16. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
Klonoff DC; Buse JB; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Wintle ME; Maggs DG
Curr Med Res Opin; 2008 Jan; 24(1):275-86. PubMed ID: 18053320
[TBL] [Abstract][Full Text] [Related]
17. Once weekly exenatide: efficacy, tolerability and place in therapy.
Wysham C; Grimm M; Chen S
Diabetes Obes Metab; 2013 Oct; 15(10):871-81. PubMed ID: 23425609
[TBL] [Abstract][Full Text] [Related]
18. Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.
Brunton S; Davidson JA
Clin Ther; 2016 Mar; 38(3):582-94. PubMed ID: 26926319
[TBL] [Abstract][Full Text] [Related]
19. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
Pujante Alarcón P; Hellín Gil MD; Román LM; Ferrer Gómez M; García Zafra MV; Tébar Massó J
Med Clin (Barc); 2012 Dec; 139(13):572-8. PubMed ID: 22209597
[TBL] [Abstract][Full Text] [Related]
20. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
Postgrad Med; 2012 Jul; 124(4):33-40. PubMed ID: 22913892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]